Company Introduction
- HOME
-
About Bukwang
- History
History
-
2020 ~
PRESENT
-
2010 ~
2019
-
2000 ~
2009
-
1960 ~
1999
-
2023
- Apr,
- A Slovakian Medical Institution Joins Phase 2 Clinical Trials of JM-010 in Europe.
- Jan,
- Acquisition of Israeli Company ‘ProteKt Therapeutics’, a Developer of Neurodegenerative
and Neuroinflammatory Disease Therapeutics.
-
2022
- Dec,
- Subsidiary Contera Pharma A/S Relocates to DTU Science Park, Denmark Headquarters,
and Inaugurates New Research Facility.
- Nov,
-
A Korean Medical Institution joins Phase 2 Clinical Trials of JM-010 in Europe.
Received President’s Award at Korea’s 36th Pharm Day Awards
- Oct,
-
Applied for Korean Ministry of Food and Drug Safety approval for lurasidone,
a new drug for schizophrenia and bipolar depression
- Aug,
-
Subsidiary Dyna Therapeutics expanded SOL-804 composition patent coverage to 32 countries
- Feb,
-
Announced strategic alliance with OCI Company Ltd
-
2021
- Nov,
- Received Ministry of Food and Drug Safety Minister’s Award at Korea’s 35th Pharm Day Awards
-
2020
- Jun,
- Exported midazolam anesthetic sedative for emergency use in COVID-19 treatment to European markets
- Apr,
- Subsidiary Contera Pharma established office in Seoul, Korea
-
2019
- Sep,
- Established JaguAhR Therapeutics with Aslan Pharmaceuticals to develop new immuno-oncology therapeutics
- Jul,
- Launched partnership with the University of Dundee in the UK to develop a new treatment for Parkinson’s disease
-
2018
- Jun,
- Became Korea’s first drug maker to acquire ISO 45001 occupational health and safety management system certificationISO45001
-
2016
- Nov,
- Acquired OHSAS 18001 and ISO 14001 certifications
- Jun,
- Subsidiary Dyna Therapeutics Co., Ltd. acquired an exclusive worldwide license for the SOL-804 prostate cancer drug
candidate from Danish firm Solural Pharma
-
2015
- Jun,
- Established subsidiary Bukwang Medica to manage OTC drug development and marketing
-
2014
- Nov,
- Acquired Contera Pharma A/S, a specialist in central nervous system disease treatment based in Copenhagen
- Jul,
- Received top audit award from Korea’s Financial Supervisory Service
- May,
- Established IT subsidiary Bukwang C&C Co., Ltd.
-
2008
- Aug,
- Received cGMP approval for new Ansan plant
- Mar,
- Received the Stone Tower Order of Industrial Service Merit at the 42nd Korea Taxpayer’s Day Awards
-
2007
- Feb,
- Received the Grand Prize at the 8th Korea New Drug Awards for Levovir
-
2006
- Nov,
-
Made Forbes Asia’s 200 Best Under A Billion list; Won Korean FDA approval for Levovir
(clevudine) for the treatment of type B hepatitis
-
2004
- Nov,
- Out-licensed hepatitis B treatment patents and technology to Japanese firm Eisai
-
2000
- May,
- Renamed Bukwang Pharmaceutical Co., Ltd.
-
1997
- Jan,
- Won government recognition for excellence in labor relations
-
1993
- Dec,
- Established central R&D center
-
1989
- Dec,
-
Commissioned 2nd plant in Ansan
-
1988
- Aug,
- Listed on the Korea Stock Exchange
-
1985
- Apr,
- Became Korea’s first drug maker to win Korea Good Manufacturing Practice (KGMP) certification
-
1962
- Mar,
- Renamed Bukwang Pharmaceutical Industry Co., Ltd.
-
1960
- Oct,
- Founded as Bukwang Trading Company Ltd.